Novelty (35 U.S.C. § 102):
The invention appears to address a significant technological challenge in the field of health monitoring. A preliminary search of the prior art did not reveal any single reference disclosing a wearable device utilizing near-infrared spectroscopy specifically for non-invasive blood glucose measurement, combined with real-time analysis and wireless data transmission. Thus, the invention, as claimed, satisfies the requirement of novelty under 35 U.S.C. § 102.
Inventive Step/Non-Obviousness (35 U.S.C. § 103):
While prior art references disclose non-invasive diagnostic devices and glucose monitoring systems, combining near-infrared spectroscopy with wearable technology and integrating advanced real-time analysis algorithms demonstrates a non-obvious advancement. A person skilled in the art would not readily combine these elements without inventive ingenuity. Thus, the invention meets the criteria for non-obviousness under 35 U.S.C. § 103.
Utility (35 U.S.C. § 101):
The invention serves a clear and practical purpose by enabling non-invasive glucose monitoring, a utility highly relevant in managing diabetes. Consequently, it fulfills the utility requirement under 35 U.S.C. § 101.
Definiteness and Enablement (35 U.S.C. § 112):
The invention’s description provides sufficient detail regarding the functionality of the wearable device, including its spectroscopy method and data analysis algorithms. The claims are specific and supported by the description, fulfilling the requirements of definiteness and enablement under 35 U.S.C. § 112.
